Scalper1 News
Biotechs may still be generally out of favor, but the group has been firming up in recent weeks, holding its own in IBD’s 197 industry group rankings. Even though large-cap names like Biogen (BIIB), Celgene (CELG) and United Therapeutics (UTHR) have come under selling pressure, there are still plenty of top-rated names in the group showing relative strength. Amgen (AMGN) is carving a first-stage cup-with-handle base with a 165.10 buy point. Drug Scalper1 News
Scalper1 News